Ozempic is not the same thing as semaglutide, but semaglutide is the active ingredient inside Ozempic. Think of it like the relationship between Tylenol and acetaminophen: one is a brand name, the other is the drug itself. Ozempic is one of several brand-name products that contain semaglutide, each approved for different medical purposes and sold at different doses.
What Semaglutide Actually Is
Semaglutide is a medication that mimics a natural hormone your body releases after eating. This hormone, called GLP-1, does several things at once: it signals your pancreas to release insulin when blood sugar rises, slows the rate at which food leaves your stomach, and acts on appetite centers in the brain to reduce hunger. Semaglutide is a synthetic version of that hormone, engineered to last much longer in the body so it can be taken just once a week (or once daily in pill form) rather than being broken down in minutes like the natural version.
Three Brand Names, One Drug
Novo Nordisk, the Danish pharmaceutical company, manufactures all three FDA-approved semaglutide products. Each targets a different condition and uses a different dose range.
Ozempic is an injectable pen approved in 2017 for adults with type 2 diabetes. It helps manage blood sugar and also reduces cardiovascular risk in people with type 2 diabetes and heart disease. The maximum dose is 2 mg per week.
Wegovy is also an injectable pen but is approved specifically for weight management in adults and children 12 and older, for treating a form of fatty liver disease, and for reducing cardiovascular risk in adults with obesity and heart disease. Its maximum dose is slightly higher at 2.4 mg per week, which is why research suggests it may produce greater weight loss than Ozempic.
Rybelsus is a daily pill form of semaglutide, approved for type 2 diabetes. Because oral semaglutide isn’t absorbed as efficiently as the injectable form, less of the drug reaches the bloodstream, and the doses are measured differently. The original formulation tops out at 14 mg daily, while a newer formulation goes up to 9 mg daily. The tablets must be swallowed whole on an empty stomach, at least 30 minutes before eating or drinking anything.
Why Ozempic Dosing Starts Low
If you’re prescribed Ozempic, you won’t start at the full dose. The first four weeks begin at just 0.25 mg once a week, which gives your body time to adjust. At week five, the dose increases to 0.5 mg. From there, your doctor may continue raising the dose in steps up to the 2 mg maximum, depending on how your blood sugar responds and how well you tolerate the medication.
This gradual approach exists because semaglutide’s most common side effects are gastrointestinal. In clinical trials, up to 44% of participants experienced nausea, up to 30% had diarrhea, and up to 24% reported constipation. Abdominal pain affected up to 20%. These effects tend to be worst during dose increases and often ease over time, which is exactly why the titration schedule is spread over weeks.
What About Compounded Semaglutide
During semaglutide shortages, compounding pharmacies began producing their own versions, often at lower prices. These are not the same as Ozempic, Wegovy, or Rybelsus, and they carry meaningful differences. No generic version of semaglutide has been approved by the FDA.
The FDA has raised specific safety concerns about compounded products. Some compounders use salt forms of the drug, such as semaglutide sodium or semaglutide acetate, which are chemically different from the base form of semaglutide used in approved products. The FDA has stated it does not have information on whether these salt forms share the same chemical and pharmacologic properties as the approved drug, and it is not aware of any lawful basis for using them in compounding.
This matters because even small molecular differences can change how a drug is absorbed, how potent it is, and what side effects it produces. A compounded semaglutide product has not gone through the same manufacturing controls or clinical testing that Ozempic has.
Why No Generic Exists Yet
Novo Nordisk’s U.S. patent on semaglutide is set to expire in 2032, which means no generic manufacturer can legally produce the drug in the United States until then (barring a successful patent challenge). The company generated roughly $14 billion in Ozempic sales alone in 2023. Patents in other countries expire sooner: China’s semaglutide patent, for example, expires in 2026.
Until generics become available, the only FDA-approved options are the three Novo Nordisk brand-name products. Each requires a prescription, and insurance coverage varies significantly depending on whether the prescription is for diabetes or weight management.
The Bottom Line on Naming
Semaglutide is the drug. Ozempic is one specific product that delivers that drug as a weekly injection for type 2 diabetes. If someone says they’re “on semaglutide,” they could be taking Ozempic, Wegovy, Rybelsus, or even a compounded version. If someone says they’re “on Ozempic,” you know the exact product, the delivery method (injection), and the condition it was prescribed for (most likely type 2 diabetes). The active ingredient is identical across the three brand-name products, but the approved uses, doses, and delivery methods are not interchangeable.